14.48
-0.43(-2.88%)
Currency In USD
| Previous Close | 14.91 |
| Open | 14.55 |
| Day High | 15 |
| Day Low | 13.9 |
| 52-Week High | 76 |
| 52-Week Low | 4.56 |
| Volume | 79,269 |
| Average Volume | 1M |
| Market Cap | 57.71M |
| PE | -5.89 |
| EPS | -2.46 |
| Moving Average 50 Days | 13.92 |
| Moving Average 200 Days | 9.37 |
| Change | -0.43 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $119 as of August 18, 2025 at a share price of $14.28. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $517.39 as of August 18, 2025 at a share price of $14.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
GlobeNewswire Inc.
Aug 14, 2025 11:30 AM GMT
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial;
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
GlobeNewswire Inc.
Jul 15, 2025 12:21 PM GMT
iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapyNEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
GlobeNewswire Inc.
Jul 11, 2025 11:30 AM GMT
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf